FCGR2B and cyclic hematopoiesis: As shown in Figure 5B,5 and 5 and Table S4B, CD3−CD5+, CD3−CD19+CD5+, CD3−CD19+CD32+, CD3−CD5+CD32+ and CD3−CD19+CD5+CD32+B cells in CH patients were higher than those in healthy controls (P = .005, .006, .008, .002 and .006, respectively).